Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide
Arterial thrombosis is a common complication in patients with Ph − myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and thrombolysis 2021, Vol.51 (1), p.112-119 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 1 |
| container_start_page | 112 |
| container_title | Journal of thrombosis and thrombolysis |
| container_volume | 51 |
| creator | Košťál, Milan Schwarz, Jiří Ovesná, Petra Penka, Miroslav Dulíček, Petr |
| description | Arterial thrombosis is a common complication in patients with Ph
−
myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34–76) and of 53 years of age (ranging from 26–74) in the control group (p 25, 0.473–0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162–2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017–3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph
−
MPN patients. |
| doi_str_mv | 10.1007/s11239-020-02175-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2416931069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2416931069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-82c207bbac80bece7dd4832de3a77194e7f4285fe501b1b1500655d0ee24c23b3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxq0K1C7bvkAPyBKXXgJjO64TblVV_kiVQAik3izHmeymTeJl7BTtG3DuI_IkmN0CEgdk2XP4fvONRx9jpwJeCgDzKgohVV2AhHyF0UV1wBZCG1WYUt48YQuoZV1oBfqIPYvxFgDqGuQhO1JSmwq0XrCHj-sf3x_4uMUhbCgMfYfkUn-PfMKwGVwcI3dTy9MaOeHgErac-njHO-dToMi7QDwmCnfIg_czEU4eX_NPGOchZZnCyF1uXfWZ2vLQ8U32xylriXDn961Pa34xuVUe0Ld4zJ52boh48liX7Mubq8-X74rrD2_fX15cF14ZnYpKegmmaZyvoEGPpm3LSskWlTNG1CWarpSV7lCDaPLRAOdat4AoSy9Vo5bsbO-b9_46Y0x27KPHYXB59TlaWYrzWgnIz5K9-Ae9DTNN-XeZqkAoXe4ouac8hRgJO7uhfnS0tQLsr8TsPjGbE7O7xGyVm54_Ws_NiO2flt8RZUDtgZilaYX0d_Z_bH8CVnykwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480135469</pqid></control><display><type>article</type><title>Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide</title><source>SpringerNature Journals</source><creator>Košťál, Milan ; Schwarz, Jiří ; Ovesná, Petra ; Penka, Miroslav ; Dulíček, Petr</creator><creatorcontrib>Košťál, Milan ; Schwarz, Jiří ; Ovesná, Petra ; Penka, Miroslav ; Dulíček, Petr ; for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms ; for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</creatorcontrib><description>Arterial thrombosis is a common complication in patients with Ph
−
myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34–76) and of 53 years of age (ranging from 26–74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458–3.043, p = 0.006), age (OR 1.017/year, 1.005–1,029, p = 0.006), male gender (OR 1.419, 1.057–1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446–0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473–0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162–2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017–3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph
−
MPN patients.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-020-02175-8</identifier><identifier>PMID: 32578055</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Age ; Antiphospholipid syndrome ; Cardiology ; Gender ; Hematology ; Hypertriglyceridemia ; Ischemia ; Medicine ; Medicine & Public Health ; Mutation ; Patients ; Risk factors ; Statistical analysis ; Stroke ; Thrombophilia ; Thrombosis ; Transient ischemic attack ; Tumors</subject><ispartof>Journal of thrombosis and thrombolysis, 2021, Vol.51 (1), p.112-119</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-82c207bbac80bece7dd4832de3a77194e7f4285fe501b1b1500655d0ee24c23b3</citedby><cites>FETCH-LOGICAL-c375t-82c207bbac80bece7dd4832de3a77194e7f4285fe501b1b1500655d0ee24c23b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-020-02175-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-020-02175-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32578055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Košťál, Milan</creatorcontrib><creatorcontrib>Schwarz, Jiří</creatorcontrib><creatorcontrib>Ovesná, Petra</creatorcontrib><creatorcontrib>Penka, Miroslav</creatorcontrib><creatorcontrib>Dulíček, Petr</creatorcontrib><creatorcontrib>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</creatorcontrib><creatorcontrib>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</creatorcontrib><title>Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Arterial thrombosis is a common complication in patients with Ph
−
myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34–76) and of 53 years of age (ranging from 26–74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458–3.043, p = 0.006), age (OR 1.017/year, 1.005–1,029, p = 0.006), male gender (OR 1.419, 1.057–1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446–0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473–0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162–2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017–3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph
−
MPN patients.</description><subject>Age</subject><subject>Antiphospholipid syndrome</subject><subject>Cardiology</subject><subject>Gender</subject><subject>Hematology</subject><subject>Hypertriglyceridemia</subject><subject>Ischemia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Stroke</subject><subject>Thrombophilia</subject><subject>Thrombosis</subject><subject>Transient ischemic attack</subject><subject>Tumors</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc9u1DAQxq0K1C7bvkAPyBKXXgJjO64TblVV_kiVQAik3izHmeymTeJl7BTtG3DuI_IkmN0CEgdk2XP4fvONRx9jpwJeCgDzKgohVV2AhHyF0UV1wBZCG1WYUt48YQuoZV1oBfqIPYvxFgDqGuQhO1JSmwq0XrCHj-sf3x_4uMUhbCgMfYfkUn-PfMKwGVwcI3dTy9MaOeHgErac-njHO-dToMi7QDwmCnfIg_czEU4eX_NPGOchZZnCyF1uXfWZ2vLQ8U32xylriXDn961Pa34xuVUe0Ld4zJ52boh48liX7Mubq8-X74rrD2_fX15cF14ZnYpKegmmaZyvoEGPpm3LSskWlTNG1CWarpSV7lCDaPLRAOdat4AoSy9Vo5bsbO-b9_46Y0x27KPHYXB59TlaWYrzWgnIz5K9-Ae9DTNN-XeZqkAoXe4ouac8hRgJO7uhfnS0tQLsr8TsPjGbE7O7xGyVm54_Ws_NiO2flt8RZUDtgZilaYX0d_Z_bH8CVnykwQ</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Košťál, Milan</creator><creator>Schwarz, Jiří</creator><creator>Ovesná, Petra</creator><creator>Penka, Miroslav</creator><creator>Dulíček, Petr</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>2021</creationdate><title>Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide</title><author>Košťál, Milan ; Schwarz, Jiří ; Ovesná, Petra ; Penka, Miroslav ; Dulíček, Petr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-82c207bbac80bece7dd4832de3a77194e7f4285fe501b1b1500655d0ee24c23b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Antiphospholipid syndrome</topic><topic>Cardiology</topic><topic>Gender</topic><topic>Hematology</topic><topic>Hypertriglyceridemia</topic><topic>Ischemia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Stroke</topic><topic>Thrombophilia</topic><topic>Thrombosis</topic><topic>Transient ischemic attack</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Košťál, Milan</creatorcontrib><creatorcontrib>Schwarz, Jiří</creatorcontrib><creatorcontrib>Ovesná, Petra</creatorcontrib><creatorcontrib>Penka, Miroslav</creatorcontrib><creatorcontrib>Dulíček, Petr</creatorcontrib><creatorcontrib>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</creatorcontrib><creatorcontrib>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Košťál, Milan</au><au>Schwarz, Jiří</au><au>Ovesná, Petra</au><au>Penka, Miroslav</au><au>Dulíček, Petr</au><aucorp>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</aucorp><aucorp>for CZEMP–Czech Group for Ph- Myeloproliferative neoplasms</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2021</date><risdate>2021</risdate><volume>51</volume><issue>1</issue><spage>112</spage><epage>119</epage><pages>112-119</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Arterial thrombosis is a common complication in patients with Ph
−
myeloproliferative neoplasms (MPN). We searched for the risk factors of stroke in MPN patients from anagrelide registry. We analyzed the potential risk factors triggering a stroke/TIA event in 249 MPN patients with previous stroke (n = 168) or Transient Ischemic Attack (TIA) (n = 140), and in 1,193 MPN control subjects (without clinical history of thrombosis). These patients were registered in a prospective manner, providing a follow-up period after Anagrelide treatment. The median age of the patients in the experimental group was of 56 years of age (ranging from 34–76) and of 53 years of age (ranging from 26–74) in the control group (p < 0.001). Using a multivariate model, we determined the following as risk factors: JAK2V617F mutation (OR 2.106, 1.458–3.043, p = 0.006), age (OR 1.017/year, 1.005–1,029, p = 0.006), male gender (OR 1.419, 1.057–1.903, p = 0.020), MPN diagnosis (OR for PMF 0.649, 0.446–0.944, p = 0.024), BMI (OR 0.687 for BMI > 25, 0.473–0.999, p = 0.05) and high TAG levels (OR 1.734, 1.162–2.586, p = 0.008), all of which were statistically significant for CMP development. Concerning the risk factors for thrombophilia, only the antiphospholipid syndrome (OR 1.994, 1.017–3.91, p = 0.048) was noteworthy in a stroke-relevant context. There was no significant difference between the blood count of the patients prior to a stroke event and the control group, both of which were under a cytoreductive treatment. We found that age, male gender, JAK2V617F mutation, previous venous thrombosis, and hypertriglyceridemia represent independent risk factors for the occurrence of a stroke in Ph
−
MPN patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32578055</pmid><doi>10.1007/s11239-020-02175-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-5305 |
| ispartof | Journal of thrombosis and thrombolysis, 2021, Vol.51 (1), p.112-119 |
| issn | 0929-5305 1573-742X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2416931069 |
| source | SpringerNature Journals |
| subjects | Age Antiphospholipid syndrome Cardiology Gender Hematology Hypertriglyceridemia Ischemia Medicine Medicine & Public Health Mutation Patients Risk factors Statistical analysis Stroke Thrombophilia Thrombosis Transient ischemic attack Tumors |
| title | Ph− myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ph%E2%88%92%20myeloproliferative%20neoplasms%20and%20the%20related%20risk%20factors%20for%20stroke%20occurrence:%20Results%20from%20a%20registry%20of%20patients%20treated%20with%20Anagrelide&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Ko%C5%A1%C5%A5%C3%A1l,%20Milan&rft.aucorp=for%20CZEMP%E2%80%93Czech%20Group%20for%20Ph-%20Myeloproliferative%20neoplasms&rft.date=2021&rft.volume=51&rft.issue=1&rft.spage=112&rft.epage=119&rft.pages=112-119&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-020-02175-8&rft_dat=%3Cproquest_cross%3E2416931069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2480135469&rft_id=info:pmid/32578055&rfr_iscdi=true |